Investigating the Effects of SGLT2 Inhibitors Combined with Aerobic Exercise on Diabetic Nephropathy via Modulation of the Hippo Pathway

Hypertension, diabetes, and other factors play a significant role in the progression of kidney disease. These harmful effects can induce renal fibrosis and eventually lead to irreversible end-stage renal disease. Aerobic exercise has been shown to alleviate the progression of kidney disease by reducing oxidative stress and inflammation. The SGLT2 inhibitor dapagliflozin lowers blood glucose levels by inhibiting the activity of the SGLT2 protein, and this glucose-lowering mechanism can act directly on the kidneys to exert therapeutic effects. Given the rising incidence of diabetic nephropathy and other kidney diseases, identifying effective and rational interventions is of great importance. The development of kidney disease is closely linked to molecular mechanisms within biological cells. Currently, interventions primarily involve pharmacological treatments and lifestyle modifications. However, few studies have examined the combined effect of aerobic exercise and SGLT2 inhibitors on kidney disease through modulation of the Hippo pathway. Therefore, this article reviews the impact of aerobic exercise combined with dapagliflozin on diabetic kidney disease via the Hippo pathway, aiming to provide insights for potential treatment strategies.